anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides potassium iodide sustained release medication and its preparation method. The preparation comprises (By weight percentage) potassium iodide 10-70%, adjuvant with sustained release effect 10-90%, and other adjuvant in balance. Adjuvant with sustained release effect is glyceryl monostearate and/or beeswax and/or carnauba wax and/or stearyl alcohol and/or stearyl alcohol and/or polyacrylic resin. The preparation method comprises granulating through fusion method, coating, tabletting or capsulating to give skeleton type agents; pressing tablet core directly or taking the skeleton type tablet as core, and coating to give membrane controlled release agent. The inventive preparation has the advantages of good sustained release and controlled release and broad basic remedy content scope. Compared with common potassium iodide preparation, the preparation has the advantages of improved stability and therapeutic effect, reduced adverse reaction and administration times. Small dose of the preparation can be used for iodine supplement, and significant dose can be used for treating acute and chronic lead poisoning.
A method of treating a subject suffering from cancer comprising administering an effective amount of a polysaccharide extract and an effective amount of a PD-1 inhibitor to the subject, wherein the polysaccharide extract comprises ginseng polysaccharides. A method of increasing the amount of tumor-infiltrating leukocytes in cancer cells in a subject; and a kit comprising the polysaccharide extract and the PD-1 inhibitor. -. Votcle(Po$) 1500 .AnibPD.I(1*rqftc) Fig. 1 Vehicle(PBS) Anti-PD-i Anti-PD-1+GP Fig. 2
Compositions and methods for treating one or more symptoms one or more symptoms such as reduced sexual desire and fecal compaction are provided. Accordingly, the disclosed composition can be administered tosubjects in need thereof, including patients with multiple sclerosis, particularly in patients in which multiple sclerosis symptoms are exacerbated in the premenstrual time period/during the menstrual period. The compositions are unit dosage forms including pharmaceutically acceptable salts of a BPC peptide. The unit dosage forms can be formulated for enteral, parenteral, or topical administration. Also provided herein are methods of increasing sexual desire or reducing fecal compaction in a subject in need thereof. In one embodiment, the compositions disclosed herein are used to alleviate one or more symptoms in patients with multiple sclerosis, particularly in patients in which multiple sclerosis symptoms are exacerbated in the premenstrual time period. The disclosed dosage forms can be administered orally or parenterally.
The invention provides a roflumilast dispersible tablet composition, which is characterized by being composed of: roflumilast, copovidone, sodium stearyl fumarate and pharmaceutically-acceptable auxiliary materials. The roflumilast dispersible tablet composition prepared through the method in the invention is good in dispersion uniformity. A common tablet needs more than 5 min to disintegrate completely, while the roflumilast dispersible tablet can be disintegrated completely only within 70 s and can pass through a 2# sieve, wherein the time is far less than 3 min specified in Chinese pharmacopoeia. The roflumilast dispersible tablet is greatly increased in disintegration speed and meanwhile is greatly increased in dissolution rate compared with the common tablets in the prior art. The dissolution rate can reach 85% at 5 min and furthermore can reach 95% at 15 min. The roflumilast dispersible tablet composition is greatly increased in bio-utilization rate.
Acebutolol hydrochloride USP is a selective, hydrophilic beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic activity for use in treating patients with hypertension and ventricular arrhythmias. It is marketed in capsule form for oral administration. Acebutolol Hydrochloride Capsules USP are provided in two dosage strengths which contain 200 mg or 400 mg of acebutolol as the hydrochloride salt. The inactive ingredients are povidone, corn starch, pregelatinized starch, and stearic acid. The capsule shells and imprinting ink for the 200 mg dosage strength also contain FD&C Blue 1, FD&C Red 40, titanium dioxide, black iron oxide, yellow iron oxide, sodium lauryl sulfate, gelatin, carboxymethylcellulose, shellac, ammonium hydroxide, propylene glycol, and potassium hydroxide. The capsule shells and imprinting ink for the 400 mg dosage strength also contain FD&C Blue 1, FD&C Red 3, titanium dioxide, FD&C Yellow 6, D&C Yellow 10, sodium lauryl sulfate, gelatin, shellac, ammonium hydroxide, propylene glycol, simethicone, and sodium hydroxide.

Acebutolol hydrochloride USP has the following structural formula:

C 18H 28N 2O 4•HCl M.W. 372.9 

Acebutolol hydrochloride USP is a white or slightly off-white powder freely soluble in water, and less soluble in alcohol. Chemically it is defined as the hydrochloride salt of (±)N-[3-Acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl] butanamide.
AIM: To evaluate the efficiency of therapy with Prostatex plus rectal suppositories in the treatment of patients with chronic abacterial prostatitis and benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: A total of 50 men with chronic abacterial prostatitis of category III A, occurring in combination with BPH, were included in the study. All patients received Prostatex plus (rectal suppositories) 1 suppository 1 time per day. The duration of treatment was 20 days. After taking the drug, patients were followed-up for 40 days. There were three follow-up visits during the study period (days 1, 20 and 60).
RESULTS: The study proved that the use of Prostatex plus rectal suppositories has a positive effect on urinary parameters, subjective and objective symptoms of chronic abacterial prostatitis and BPH, which allowed to recommend it for this group of patients, according to the following scheme: 1 suppository 1 time per day for 20 days.
AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
Participants in the control group will receive enhanced usual care and will not take part in cognitive behavioral therapy sessions or exercise sessions. The EUC group will receive the American Diabetes Association "Diabetes Basics" web series (one video per week for 10 weeks) or "Diabetes Basics" handouts sent via mail.
The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A, and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and growth of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-.alpha.), which is a pro-inflammatory cytokine, interleukin-1.beta. (IL-1.beta.), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF). Therefore, the macrolactin compounds produced by the Bacillus polyfermenticus KJS-2 strain according to the present invention can provide excellent anti-inflammatory agents.
The present application provides methods and compositions for treating and preventing disease associated with polyglutamine protein expansion. For example, the application provides peptoid compounds that selectively bind polyglutamine expanded polypeptides. Methods for using such compounds for treatment, prevention and detection of polyglutamine expansion disorders, such as Huntington's disease, are likewise provided. In addition, methods and compositions for treating and preventing neuronal disorders linked to pathogenic protein aggregation are disclosed. For example, the application provides peptoid compounds that selectively bind to Αβ42. Methods for using such compounds for treatment and prevention of symptoms of Alzheimer's disease are likewise provided.
The shift to a genotype-first approach in genetic diagnostics has revolutionized our understanding of neurodevelopmental disorders, expanding both their molecular and phenotypic spectra. Kleefstra syndrome (KLEFS1) is caused by EHMT1 haploinsufficiency and exhibits broad clinical manifestations. EHMT1 encodes euchromatic histone methyltransferase-1-a pivotal component of the epigenetic machinery. We have recruited 209 individuals with a rare EHMT1 variant and performed comprehensive molecular in silico and in vitro testing alongside DNA methylation (DNAm) signature analysis for the identified variants. We (re)classified the variants as likely pathogenic/pathogenic (molecularly confirming Kleefstra syndrome) in 191 individuals. We provide an updated and broader clinical and molecular spectrum of Kleefstra syndrome, including individuals with normal intelligence and familial occurrence. Analysis of the EHMT1 variants reveals a broad range of molecular effects and their associated phenotypes, including distinct genotype-phenotype associations. Notably, we showed that disruption of the "reader" function of the ankyrin repeat domain by a protein altering variant (PAV) results in a KLEFS1-specific DNAm signature and milder phenotype, while disruption of only "writer" methyltransferase activity of the SET domain does not result in KLEFS1 DNAm signature or typical KLEFS1 phenotype. Similarly, N-terminal truncating variants result in a mild phenotype without the DNAm signature. We demonstrate how comprehensive variant analysis can provide insights into pathogenesis of the disorder and DNAm signature. In summary, this study presents a comprehensive overview of KLEFS1 and EHMT1, revealing its broader spectrum and deepening our understanding of its molecular mechanisms, thereby informing accurate variant interpretation, counseling, and clinical management.
Neurodevelopmental Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS) is caused by changes in the IRF2BPL gene. Variants in the gene can also lead to other neurodevelopmental presentations. Due to the limited number of cases that have been described to date, clinicians may have a limited understanding of what types of symptoms can develop in affected individuals and at what age. The purpose of the study is to gather clinical information about progression, treatments and outcomes for patients with variants in IRF2BPL. The investigators will collect information about medical history, growth, development, treatments and the results of previous genetic tests. In some cases, the investigators may also collect tissue samples. This is a non-interventional study that will expand the current understanding of the range of health concerns that can be seen in individuals with changes in the IRF2BPL gene by collecting medical information and samples from a larger group of affected individuals.
The invention relates to a plant Chinese herbal medicine essence complex disinfectant which is widely used in washing and disinfecting in daily lives, and is suitable for various fields in people's daily lives. The product provided by the invention is extracted from pure Chinese herbal medicine essences, and is strictly screened and formulated. According to the invention, golden thread and largehead atractylodes rhizome are adopted as main medicines, and Chinese herbal medicines such as amur corktree bark, officinal magnolia bark, Baikal skullcap root, and honeysuckle flower are adopted as auxiliary medicines. The main medicines and the auxiliary medicines provide a synergetic effect and an adducting effect. The complex disinfectant is advantaged in high-efficiency bactericidal effect, no side effect, no damage to human skins, no volatile irritating odor, no corrosion to disinfected object, and long-lasting effect. The invention leads a novel direction of the disinfection field.
Sarcoidosis, a systemic inflammatory disease, poses challenges in understanding its etiology and variable clinical courses. Despite ongoing uncertainty about causative agents and genetic predisposition, granuloma formation remains its hallmark feature. To address this, we developed a validated in vitro human granuloma model using patient-derived peripheral blood mononuclear cells (PBMCs), offering a dynamic platform for studying early granuloma formation and sarcoidosis pathogenesis. However, a current limitation of this model is its dependence on freshly isolated PBMCs obtained from whole blood. While cryopreservation is a common method for long-term sample preservation, the biological effects of freezing and thawing PBMCs on granuloma formation remain unclear. This study aimed to assess the viability and functionality of cryopreserved sarcoidosis PBMCs within the granuloma model, revealing similar granulomatous responses to fresh cells and highlighting the potential of cryopreserved PBMCs as a valuable tool for studying sarcoidosis and related diseases.
Systems and methods that include configurations of a medical device, user device and service platform are described. Embodiments may include a secure network to run medical applications that control and/or monitor the medical device. An online store may be provided for storing and distributing medical applications to the user device and medical device. A secure environment may be provided within the user device and medical device that protects the integrity of medical applications running on those devices. A service platform may provide a service that enables a medical authority to certify and monitor the medical applications. In some implementations, various third parties and the user of the user device may be allowed to manage and monitor the medical device.
PURPOSE: A Perillae semen extract is provided to effectively suppress airway hyperreactivity, to prevent and treat asthma, and to be used as a material of a pharmaceutical composition and a health functional food for treating asthma. CONSTITUTION: A composition for preventing or treating asthma contains a Perillae semen extract as an active ingredient. The extract is prepared using water. The composition is administered to an individual in 0.5-60 mg/g bwt of the composition. An inducer for immunotolerance contains the extract as an active ingredient, which promotes IL-10 generation. A health functional food for preventing or treating asthma contains the extract as an active ingredient.
Administer RASI, with or without other antihypertensives except for CCB, and blood pressure should be controlled within the target range (140/90 mmHg). RASI intaking starts at least 5 days before stenting.
Veterinary programs traditionally teach gross anatomy by having students perform regional dissections on animal cadavers. Dissection is effective but also costly, time consuming, and intimidating for students. These factors, along with reduced contact hours devoted to gross anatomy, warrant investigation of more time-efficient teaching modalities. We sought to determine whether learning anatomy from instructor-prosected cadavers is a suitable alternative to in-class cadaveric dissections. Veterinary students completed nine units of regional gross anatomy over three courses. For each unit, students were randomly assigned to study the region on instructor-prosected cadavers (i.e., prosection students, n = 25) or perform their own dissection of the region in small groups (i.e., dissection students, n = 25). Prosection students spent on average 18 minutes/week less (p < .05) in class than dissection students. Despite comparable amounts of time spent studying outside of class each week, prosection students outperformed (p < .05) dissection students on 56% of the practical unit exams and 44% of the overall unit exams, whereas dissection students outperformed (p < .05) prosection students on only a single unit exam. Prosection students also performed better (p < .05) on subsequent quizzes administered to assess knowledge retention. Survey responses indicated that students were more confident in the accuracy of prosections and valued the efficiency they provided. Although they found value in performing dissections and were generally satisfied with the knowledge they gained, many students reported feeling timid toward dissecting, which diminished the experience. Together, these findings demonstrate that expertly prosected cadavers were more time-efficient than in-class cadaveric dissections and were generally more effective for learning gross veterinary anatomy.
Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
Leflunomide is a pyrimidine synthesis inhibitor. The chemical name for leflunomide is N-(4´-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide. It has a molecular formula C12H9F3N2O2, a molecular weight of 270.2 and the following structural formula:

  
  


Leflunomide tablets USP are available for oral administration as tablets containing 10 mg or 20 mg of active drug. Combined with leflunomide are the following inactive ingredients: colloidal silicon dioxide, crospovidone, glyceryl monocaprylocaprate type 1, lactose monohydrate, magnesium stearate, polyvinyl alcohol-part. hydrolyzed, povidone, pregelatinized starch (maize), sodium lauryl sulfate, talc and titanium dioxide. In addition 20 mg tablet contains iron oxide yellow.
Bortezomib has become commercially available in the European Union in May 2004 for the third line treatment of patients with multiple myeloma. The registration was based on two phase II studies while more research was ongoing. Some experience was already gained with the use of this product in the Netherlands by means of a compassionate use program before the initial registration. However, the data available from the use of bortezomib in daily clinical practice is limited. Therefore, there is a need to closely study the use of bortezomib in daily clinical practice. During the course of the study, the registration of bortezomib was extended. In April 2005, bortezomib was registered for second line treatment of multiple myeloma. Consequently, safety and effectiveness data from patients in this line of treatment could be collected in this project as well (arm A). Data of a large phase 3 trial showed that response rates differ between patients treated for multiple myeloma in the second line and patients treated in the third line. Therefore the protocol was amended to compare the response rates in two arms, dependent on the number of previous treatment lines for multiple myeloma: The protocol was also amended to determine the time to progression and response rate in both patients who received thalidomide earlier versus patients who didn't (arm B). ARM A: Patients with relapsed multiple myeloma who have received not more than 1 previous line of treatment and show progression on that therapy; ARM B: Patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of treatment and show progression on most recent therapy. This project is a 'post authorization study (PAS)'. This means that only routinely available medical data is collected, with the patients' permission, and no additional interventions or diagnostic procedures should be done specifically for this study. Because the study is observational, dosage, administration and duration of treatment is at discretion of treating physician.
Background: Gouty arthritis causes severe pain and inflammation. Alginate oligosaccharides (AOSs) are natural products derived from alginate and have anti-inflammatory properties. We explored the potential effects of AOSs with different degrees of polymerization (Dp) on gouty arthritis and associated mechanisms. Methods: We established a mouse model of gouty arthritis by injecting monosodium urate (MSU) into ankle joint. Nocifensive behavior, gait and ankle swelling were used to study AOS's effects. Biochemical assays, in vivo imaging, live cell Ca2+ imaging, electrophysiology, RNA-sequencing, etc. were used for mechanism exploration. Results: AOS2 (Dp=2), AOS3 (Dp=3) and AOS4 (Dp=4) all inhibited ankle swelling, whereas AOS2&3 produced the most obvious analgesia on model mice. AOS3, which was picked for further evaluation, produced dose-dependent ameliorative effects on model mice. AOS3 reversed gait impairments but did not alter locomotor activity. AOS3 inhibited NLRP3 inflammasome activation and inflammatory cytokine up-regulation in ankle joint. AOS3 ameliorated MSU-induced oxidative stress and reactive oxygen species (ROS) production both in vivo and in vitro and reversed the impaired mitochondrial bioenergetics. AOS3 activated the Nrf2 pathway and promoted Nrf2 disassociation from Keap1-bound complex and Nrf2 nuclear translocation, thus facilitating antioxidant gene expression via Nrf2-dependent mechanism. Nrf2 gene deficiency abolished AOS3's ameliorative effects on pain, inflammation and oxidative stress in ankle joints of model mice. AOS3 reduced TRPV1 functional enhancement in DRG neurons and constrained neuroactive peptide release. Conclusions: AOS3 ameliorates gouty arthritis via activating Nrf2-dependent antioxidant signaling, resulting in suppression of ROS-mediated NLRP3 inflammasome activation and TRPV1 enhancement. AOS3 may be novel therapeutics for gouty arthritis.
FIELD: medicine, cardiology, pharmacology. SUBSTANCE: group of inventions comprises agent containing nicotinic acid and dried defibrinated blood of Siberian stag, Manchurian wapiti or sika deer taken in the following ratio of components, %: dried defibrinated Siberian stag blood, 99.0-1.0; nicotinic acid, 1.0-99.0. Food supplement comprises nicotinic acid and dried defibrinated blood of Siberian stag, Manchurian wapiti or sika deer in the following ratio of components, %: defibrinated Siberian stag, 99.0-1.0; nicotinic acid, 1.0-99.0. Method of treatment involves prescription of dietotherapy of the proposed agent in the dose 1 capsule, 3 times per a day, for 21 days. Invention expands assortment of agents eliciting antihyperlipoproteinemic activity, enhancement of treatment effectiveness and reduction of adverse effects. EFFECT: enhanced effectiveness of supplement and treatment. 3 cl, 9 tbl
A medicament to treat collagen damage (e.g. as in polyarthritis chronica contains the reaction prod. of alkali metal phosphate citrate complexes of di- and/or tri-valent Fe, Co and/or Mn with glyceryl esters of tribasic acids as the active ingredient. The formulation also contains small amts. of glycerides of natural vegetable fatty acids, nonionic emulsifiers and/or polyoxyethylene derivs. of sorbitol anhydride opt. partially esterified with fatty acids. The formulation are stable for >=1 yr. in air-tight containers. The additives are skin-compatible and do not cause allergic reactions.
Cord clamping will be performed before 30 seconds after delivery, annoting the exact time of clampage and initiating reanimation and postnatal care procedures as usual. 60 second after delivery of the new born, 10 IU of Oxytocin will be administered intramuscularly.